Bruker Stock (NASDAQ:BRKR)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$35.05

52W Range

$28.53 - $56.22

50D Avg

$43.71

200D Avg

$40.09

Market Cap

$5.14B

Avg Vol (3M)

$2.33M

Beta

1.19

Div Yield

$0.20 (0.59%)

BRKR Company Profile


Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.

Show More

Industry

Medical - Devices

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

11,396

IPO Date

Aug 04, 2000

Website

BRKR Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24Dec 23
Product$2.77B$2.76B$2.46B
Product and Service, Other$670.10M$607.20M$13.10M
Service--$493.80M

Fiscal year ends in Dec 25 | Currency in USD

BRKR Financial Summary


Dec 25Dec 24Dec 23
Revenue$3.44B$3.37B$2.96B
Operating Income$216.60M$253.10M$436.90M
Net Income$-8.60M$113.10M$427.20M
EBITDA$436.90M$438.60M$675.50M
Basic EPS$-0.15$0.76$2.92
Diluted EPS$-0.15$0.76$2.90

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q4 25Feb 12, 26 | 8:30 AM
Q3 25Nov 03, 25 | 8:30 AM
Q2 25Aug 04, 25 | 8:30 AM

Peer Comparison


TickerCompany
KRYSKrystal Biotech, Inc.
IRTCiRhythm Technologies, Inc.
BTSGBrightSpring Health Services, Inc. Common Stock
MMSIMerit Medical Systems, Inc.
CHEChemed Corporation
CRSPCRISPR Therapeutics AG
TFXTeleflex Incorporated
GKOSGlaukos Corporation
TMDXTransMedics Group, Inc.
TGTXTG Therapeutics, Inc.